drugset / Trial / NCT05044195
A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This Phase 3 study is a randomized, observer-blind immunogenicity and safety study of aQIV (an MF59-adjuvanted quadrivalent influenza vaccine) compared with a licensed quadrivalent influenza vaccine in adults 50 to 64 years of age.
Timeline
- Start
- 2021-09-30
- Primary completion
- 2022-01-18
- Completion
- 2022-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Comparator QIV | Vaccine | 0.5 ml | Intramuscular |
| Subject | aQIV | Vaccine | 0.5 ml | Intramuscular |